Münchhalfen, Matthias https://orcid.org/0000-0002-9240-9342
Görg, Richard https://orcid.org/0000-0003-4513-8698
Haberl, Michael https://orcid.org/0009-0002-3586-8435
Löber, Jens
Willenbrink, Jakob
Schwarzt, Laura
Höltermann, Charlotte
Ickes, Christian https://orcid.org/0009-0008-8717-1713
Hammermann, Leonard https://orcid.org/0009-0009-7159-7581
Kus, Jan
Chapuy, Björn
Ballabio, Andrea https://orcid.org/0000-0003-1381-4604
Reichardt, Sybille D. https://orcid.org/0000-0002-5316-2690
Flügel, Alexander
Engels, Niklas https://orcid.org/0000-0003-2341-4954
Wienands, Jürgen https://orcid.org/0000-0001-8278-7668
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (TRR 274, Project A08, TRR 274, Project A08, TRR 274/2 2024 - 408885537, SFB 1328, Project A01 - 335447717, TRR 274/2 2024 - 408885537, SFB 1328, Project A01 - 335447717, TRR 274/2 2024 - 408885537, SFB 1328, Project A01 - 335447717)
EC | Horizon 2020 Framework Programme (Grant agreement No. 101021345 (T-Neuron), Grant agreement No. 101021345 (T-Neuron), Grant agreement No. 101021345 (T-Neuron))
Article History
Received: 28 March 2024
Accepted: 31 July 2024
First Online: 14 August 2024
Competing interests
: A. Ballabio is co-founder of CASMA Therapeutics and an advisory board member of Next Generation Diagnostics and Avilar Therapeutics. All other authors declare no competing interests.